Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval ...
TipRanks on MSN
Vizsla, Coty, Kalaris, Annexon, Brown & Brown trending
Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...
Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...
International Business Machines Corporation IBM has surged 33% over the past year compared with the industry’s growth of 79.1%, driven by a strong demand for hybrid cloud and ar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback